Milestone launches CARDAMYST nasal spray for PSVT via U.S. retail pharmacies

Milestone Pharmaceuticals Inc.

CARDAMYST (etripamil) is now available through U.S. retail pharmacies as first self-administered PSVT treatment.
National sales force deployment set for mid-February 2026 to support commercialization.
Eligible commercially insured patients receive a $25 copay cap via patient assistance program.
FDA approved CARDAMYST on December 12, 2025 — first PSVT therapy approved in over 30 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.